

Supplementary Table S4. ARQ 531 and Gilteritinib efficacy in primary patient's samples

ARQ 531			
Concentration (µM) Comparison	Estimated Ratio	95% CI	P-value
0.005 Versus Vehicle	0.91	(0.79, 1.05)	0.438
0.01 Versus Vehicle	0.95	(0.82, 1.1)	0.936
0.05 Versus Vehicle	0.92	(0.79, 1.06)	0.489
0.1 Versus Vehicle	0.9	(0.78, 1.04)	0.259
0.5 Versus Vehicle	0.69	(0.6, 0.8)	<.001
1 Versus Vehicle	0.58	(0.5, 0.68)	<.001
5 Versus Vehicle	0.34	(0.25, 0.48)	<.001
10 Versus Vehicle	0.28	(0.15, 0.52)	<.001
50 Versus Vehicle	0.09	(0, 2.04)	0.158
Gilteritinib			
Concentration (µM) Comparison	Estimated Ratio	95% CI	P-value
0.005 vs. 0 (DMSO)	1.02	(0.89, 1.17)	>.999
0.01 vs. 0	1.05	(0.92, 1.21)	0.926
0.05 vs. 0	1.06	(0.92, 1.21)	0.889
0.1 vs. 0	1.02	(0.89, 1.17)	>.999
0.5 vs. 0	0.99	(0.86, 1.13)	>.999
1 vs. 0	0.87	(0.76, 1)	0.05
5 vs. 0	0.78	(0.67, 0.9)	<.001
10 vs. 0	0.56	(0.47, 0.66)	<.001
50 vs. 0	0.54	(0.3, 0.98)	0.041